Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Family Medicine | Geriatrics | Internal Medicine | Critical Care | Emergency Medicine | Nursing | Oncology | Pharmacy | Pulmonology | Institutional

Back to Journal Articles

FDA Approves Expanded Use of Xarelto

Last Updated: November 05, 2012.

MONDAY, Nov. 5 (HealthDay News) -- Approval of the anti-clotting drug Xarelto (rivaroxaban) has been expanded by the U.S. Food and Drug Administration to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.

Xarelto was approved last year to treat clots stemming from knee or hip replacement and to lessen the risk of stroke in people with non-valvular atrial fibrillation.

The drug's newest approvals were given based on clinical studies involving 9,478 people, the FDA said in a news release. As with other anti-clotting drugs, bleeding is the most common side effect.

Xarelto is produced by Janssen Pharmaceuticals, based in Raritan, N.J.

More information

The FDA has more about this approval.

Previous: American Society for Radiation Oncology, Oct. 28-31, 2012 Next: Antirheumatic Drugs Have Minor Effect on Preeclampsia Risk

Reader comments on this article are listed below. Review our comments policy.

Submit your opinion: